Clinical applications of dosimetry for mIBG therapy

Q J Nucl Med Mol Imaging. 2011 Apr;55(2):116-25.


Metaiodobenzylguanidine (mIBG), developed 30 years ago, is taken up by tumours expressing the noradrenaline transporter. Radiolabelled with I-123 or I-131, mIBG has become a gold standard for diagnostic imaging of pediatric and adult neuroendocrine cancer. Within a few years of its clinical introduction, I-131 mIBG was found to be an effective palliative treatment with minimal toxicity that in some cases could produce a complete response. The importance of internal dosimetry for I-131 mIBG therapy has been demonstrated by a number of studies showing that absorbed doses delivered to tumours and organs-at-risk from standard and weight-based activities can vary by an order of magnitude. However, significant correlations between the whole-body absorbed dose and myelotoxicity have been demonstrated and studies based on this relationship have enabled treatments to be tailored to the individual. Ongoing developments include patient-specific treatment planning based on tumour dosimetry and cocktails of radionuclides and radiosensitisers.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 3-Iodobenzylguanidine / administration & dosage
  • 3-Iodobenzylguanidine / therapeutic use*
  • Adult
  • Child
  • Humans
  • Iodine Radioisotopes / administration & dosage
  • Iodine Radioisotopes / therapeutic use*
  • Neuroendocrine Tumors / diagnostic imaging
  • Neuroendocrine Tumors / radiotherapy
  • Radionuclide Imaging
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy Planning, Computer-Assisted


  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine